SHARE NOW
Clinical stage gene therapy company, LEXEO Therapeutics, LEXEO, announced the strategic investment from Sarepta Therapeutics, Inc., Sarepta, to support the advancement of LEXEO’s AAV gene therapy programs. The companies plan to explore collaboration opportunities within LEXEO’s preclinical cardiovascular pipeline. The financial details of the investment were not disclosed.
LEXEO focuses on advancing gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined sub-group of Alzheimer’s disease. ‘LEXEO’s pipeline has the potential to treat the underlying root cause of disease addressing up to one million patients in the United States across a diverse range of cardiomyopathies with significant unmet need.’
“We are excited by the potential of LEXEO’s pipeline to deliver a new future for patients with devastating genetic cardiovascular diseases,” Sarepta’s President and CEO, Doug Ingram, commented.
In the Western world, cardiovascular disease is the most significant cause of morbidity and mortality; rapidly becoming a primary cause of death worldwide. Cardiomyopathy can be commonly caused by genetic mutations, with over 50 distinct genes implicated in dilated cardiomyopathy alone.
“Sarepta’s investment in LEXEO aligns with our vision of expanding the promise of gene therapy. Our recent advancements in next-generation capsid development and suspension-based manufacturing, including MyoAAV, will give us the capabilities to develop treatments for large, under-served indications including cardiomyopathies,” added Ingram.
How are you enjoying this news article? Let us know your thoughts, here >>
LEXEO’s foundation science derives from partnerships and exclusive licenses with leading academic laboratories at Weill Cornell Medicine and the University of California, San Diego. Its diverse AAV-based gene therapy candidate pipeline is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization.
R. Nolan Townsend, CEO of LEXEO adds to the reasoning behind the strategic collaboration that this investment brings:
“Sarepta is an established leader in bringing life-changing genetic medicine to patients and we are excited by its strategic investment in LEXEO. The addition of Sarepta as an investor is an important milestone that reinforces the therapeutic value and market opportunity of our cardiovascular pipeline.”
Source: LEXEO Press Release
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
